RxDoctor Payments Data

Richard Gergoudis, MD

Family Medicine · Richmond, VANPI 1962441881

Payments from drug & device makers

$7,404in general payments, 2019–2025

Across 464 payments — averaging $15.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$716
  • AstraZeneca$488
  • Phathom Pharmaceuticals, Inc.$453
  • Amgen$386
  • Takeda Pharmaceuticals U.S.A., Inc.$365
  • plus $3K from 50 others

What the payments were for

  • Food & beverage$7,385100%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,404 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$516,843
Medicare patients
977
Services billed
17,098

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$102,861
EliquisApixaban92$99,102
OzempicSemaglutide51$63,797
TrulicityDulaglutide44$48,182
FarxigaDapagliflozin Propanediol33$33,692
XareltoRivaroxaban19$23,255
MyrbetriqMirabegron26$21,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,165
MounjaroTirzepatide15$14,623
Breo ElliptaFluticasone/Vilanterol26$11,694
Atorvastatin Calcium1,050$8,530
SynthroidLevothyroxine Sodium89$7,244
Rosuvastatin Calcium492$7,144
Valsartan257$5,812
Levothyroxine Sodium635$5,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$716$103,306129 claims
Boehringer IngelheimJardiance$128$102,86183 claims
Novo NordiskOzempic$206$63,79751 claims
Lilly USA, LLCTrulicity, Mounjaro$205$62,80559 claims
AstraZenecaFarxiga, Symbicort$488$36,42145 claims
GSKTrelegy Ellipta, Breo Ellipta$317$30,85946 claims
Johnson & JohnsonXarelto$153$23,25519 claims
Astellas Pharma US IncMyrbetriq$29$21,58426 claims
AbbVieSynthroid, Lexapro$1,768$12,387101 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$37$5,792635 claims
Almatica Pharma LLCSertraline Hcl$39$1,741214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →